Corina E. Dutcus
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Papers in
-
- Thyroid Cancer Diagnosis and Treatment 26
- Hepatology 14
- Hepatocellular Carcinoma Treatment and Prognosis 14
- Co-authors
- Matthew Hiram Taylor (22 shared papers)Marcia S. Brose (16 shared papers)Makoto Tahara (19 shared papers)Naomi Kiyota (13 shared papers)Lori J. Wirth (13 shared papers)Andrew George Gianoukakis (9 shared papers)Steven I. Sherman (11 shared papers)Robert John Motzer (9 shared papers)
- Journals
- Annals of Oncology (20 papers)European Journal of Cancer (8 papers)Journal of Clinical Oncology (6 papers)The Lancet Oncology (4 papers)The Lancet (3 papers)
- Partner nations
- United StatesJapanUnited Kingdom
In The Last Decade
Corina E. Dutcus
77 papers receiving 13.8k citations
Corina E. Dutcus's Hit Papers
Peers
Comparison fields: 5 of 103
- Hepatology 4.9k
- Oncology 2.9k
- Endocrinology, Diabetes and Metabolism 2k
- Pulmonary and Respiratory Medicine 2.5k
- Cancer Research 785
Countries citing papers authored by Corina E. Dutcus
This map shows the geographic impact of Corina E. Dutcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corina E. Dutcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corina E. Dutcus more than expected).
Fields of papers citing papers by Corina E. Dutcus
This network shows the impact of papers produced by Corina E. Dutcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corina E. Dutcus. The network helps show where Corina E. Dutcus may publish in the future.
Co-authors
The 25 scholars most cited alongside Corina E. Dutcus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Hit paper breakdown → | 2018 | 4424 |
| 2 | Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Hit paper breakdown → | 2015 | 1602 |
| 3 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1353 |
| 4 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 968 |
| 5 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Hit paper breakdown → | 2011 | 921 |
| 6 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Hit paper breakdown → | 2015 | 782 |
| 7 | Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer Hit paper breakdown → | 2020 | 414 |
| 8 | Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2019 | 401 |
| 9 | 2015 | 375 | |
| 10 | Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors Hit paper breakdown → | 2020 | 349 |
| 11 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 326 |
| 12 | Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study Hit paper breakdown → | 2025 | 158 |
| 13 | 2017 | 156 | |
| 14 | 2015 | 109 | |
| 15 | 2019 | 109 | |
| 16 | 2019 | 98 | |
| 17 | 2017 | 90 | |
| 18 | 2018 | 89 | |
| 19 | 2018 | 88 | |
| 20 | 2018 | 74 |
About Corina E. Dutcus
Corina E. Dutcus is a scholar working on Endocrinology, Diabetes and Metabolism, Hepatology, Oncology, Obstetrics and Gynecology and Pulmonary and Respiratory Medicine, having authored 81 papers that have together received 14.1k indexed citations. Recurring topics across this work include Thyroid Cancer Diagnosis and Treatment (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Immunotherapy and Biomarkers (10 papers), Renal cell carcinoma treatment (9 papers), Endometrial and Cervical Cancer Treatments (8 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (5 papers) and Head and Neck Cancer Studies (2 papers). The work is most often cited by research in Hepatology (4.9k citations), Oncology (2.9k citations), Endocrinology, Diabetes and Metabolism (2k citations), Pulmonary and Respiratory Medicine (2.5k citations) and Cancer Research (785 citations). Corina E. Dutcus has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Matthew Hiram Taylor, Marcia S. Brose, Makoto Tahara, Naomi Kiyota, Lori J. Wirth, Andrew George Gianoukakis, Steven I. Sherman, Robert John Motzer, Bruce G. Robinson and Martin Jean Schlumberger. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, The Lancet Oncology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.